Wuhan YZY Biopharma Co Ltd (hkse:02496) Share Price

Company Profile

Business description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer, and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The company has designed and developed various clinical-stage candidate drug pipelines, such as M701 (EpCAM CD3 bispecific antibody), Y101D, Y150, Y2019 (RBD dimer subunit SARS-CoV-2 vaccine), M802, and Y400 (VEGFxANG2 bispecific antibody) for the treatment of different cancer and age-related complications. Geographically, the company derives all of its revenue from the People's Republic of China (PRC).
Contact
No. 666 Gaoxin Road
Building C2-1, Guanggu Biocity
East Lake High Tech Development Zone
Hubei Province
Wuhan
CHN
T: +86 2782668988
http://www.yzybio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
106

Recommended

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.

Joseph Taylor | 16 September 2025

Working to prevent repeated failures could also improve competitiveness.

Nathan Zaia | 15 September 2025

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Roy Van Keulen | 15 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,151.20	1.30	-0.01%
CAC 40	7,818.22	78.71	-1.00%
DAX 40	23,329.24	419.62	-1.77%
Dow JONES (US)	45,792.82	90.63	-0.20%
FTSE 100	9,195.66	81.37	-0.88%
HKSE	26,438.51	8.05	-0.03%
NASDAQ	22,355.86	7.12	0.03%
Nikkei 225	44,902.27	134.15	0.30%
NZX 50 Index	13,234.89	26.58	0.20%
S&P 500	6,614.29	0.99	-0.01%
S&P/ASX 200	8,877.70	3.00	-0.03%
SSE Composite Index	3,861.86	1.36	0.04%